1085458-63-4 Usage
Chemical structure
A synthetic cannabinoid with a complex chemical structure.
Receptor selectivity
Acts as a potent and selective agonist of the cannabinoid receptors CB1 and CB2.
Therapeutic applications
Studied for potential use in treating pain, inflammation, and neurodegenerative diseases.
Anti-cancer potential
Investigated for its potential as an anti-cancer agent, with some studies showing promising results.
Psychoactive effects
Can cause hallucinations, paranoia, and anxiety in high doses.
Pharmacological profile
Has a complex pharmacological profile that requires further research to fully understand its potential benefits and risks.
Synonyms
Also known as WIN 55,212-2.
Research focus
Widely studied for its potential therapeutic applications and anti-cancer properties.
Dosage considerations
Careful consideration of dosage is necessary due to its psychoactive effects at high doses.
Ongoing research
Further research is needed to fully understand the potential benefits and risks of 10-Benzyl-8-oxa-3,10-diaza-bicyclo[4.3.1]decane.
Check Digit Verification of cas no
The CAS Registry Mumber 1085458-63-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,5,4,5 and 8 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1085458-63:
(9*1)+(8*0)+(7*8)+(6*5)+(5*4)+(4*5)+(3*8)+(2*6)+(1*3)=174
174 % 10 = 4
So 1085458-63-4 is a valid CAS Registry Number.
1085458-63-4Relevant academic research and scientific papers
SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF
-
, (2019/01/07)
The present application relates to novel imidazopyridinyl-or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.
OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 34, (2009/01/20)
The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
